Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Metastasis | Research article

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study

Authors: Annalisa Zeppellini, Stefania Galimberti, Biagio Eugenio Leone, Claudia Pacifico, Francesca Riva, Federica Cicchiello, Serena Capici, Claudia Maggioni, Luca Sala, Marina Elena Cazzaniga

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Tumor microenvironment (TME) is a dynamic setting and changes in TILs and their subpopulations are potential candidates to influence the metastatic process. Aim of this pilot study is to describe the changes occurring between primary breast cancers and their paired metastases in terms of TILs composition. To assess if these changes influence the process of metastasis development, we used a control group of patients.

Methods

We retrospectively identified 18 Luminal patients, for whom primary and metastatic tissue were available (cases) and 18 paired-matched patients (controls), not relapsed after at least 9 years of follow-up, and we quantified TILs and their composition (i.e. T CD8+ and CD4+/FOXP3+). The presence of TILs was defined as ≥10%.

Results

Our results showed that the microenvironment composition of relapsed patients was poor of TILs (median = 5%, I-III quartiles = 0.6–5%), CD8+ (2.5%, 0–5%) and CD4+/FOXP3 + (0%, 0–0.6%) in the primary tumor. Comparable results were observed in their related metastases (TILs 3.8%, 0.6–5%; CD8+ 0%, 0–1.3%; CD4+/FOXP3+ 0%,0–1.9%). On the contrary, the microenvironment in the control group was richer of TILs (5%, 5–17.5%) in comparison to cases, both in primary tumor (p = 0.035) and related metastases (p = 0.018). Although CD8+ in controls were similar to cases at primary tumor (p = 0.6498), but not at metastasis (p = 0.0223), they expressed only one part on the TILs subpopulations (p = 0.0060), while TILs in the cases at primary tumor were almost completely CD8+ (p = 0.5034).

Conclusions

These findings suggest that the lack of activation of immune system in the primary tumor might influence the multifactor process of cancer progression.
Literature
9.
go back to reference Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast Cancer trial in node-positive breast Cancer comparing the addition of Docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–7 https://doi.org/10.1200/JCO.2011.41.0902.CrossRef Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast Cancer trial in node-positive breast Cancer comparing the addition of Docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–7 https://​doi.​org/​10.​1200/​JCO.​2011.​41.​0902.CrossRef
28.
go back to reference Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas P, Virassamy B, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24:986–93 https://doi.org/10.1038/s41591-018-0078-7.CrossRef Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas P, Virassamy B, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24:986–93 https://​doi.​org/​10.​1038/​s41591-018-0078-7.CrossRef
Metadata
Title
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study
Authors
Annalisa Zeppellini
Stefania Galimberti
Biagio Eugenio Leone
Claudia Pacifico
Francesca Riva
Federica Cicchiello
Serena Capici
Claudia Maggioni
Luca Sala
Marina Elena Cazzaniga
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07960-z

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine